CPA
EWTX icon

Capital Performance Advisors’s Edgewise Therapeutics EWTX Stock Holding History

Capital Performance Advisors’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20
Closed -$534 – 989
2024
Q3 		$534 Buy
+20
New +$398 ﹤0.01% 2217

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Capital Performance Advisors's EWTX Position: Q4 2024 in Review

Capital Performance Advisors sold out of Edgewise Therapeutics (EWTX) in Q4 2024, closing a stake of 20 shares — an estimated $534 sold.

Capital Performance Advisors first reported a position in EWTX in Q3 2024 and held it in 1 quarter. The position peaked at $534 in Q3 2024. 200 funds tracked by Wall St. Rank hold EWTX as of Q4 2024.

  • Capital Performance Advisors reported no remaining Edgewise Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 20 Edgewise Therapeutics shares in Q4 2024, an estimated $534.
  • Capital Performance Advisors first reported a position in Edgewise Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Edgewise Therapeutics position peaked at $534 in Q3 2024.
  • 200 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.